PharmaEngine Total Liabilities
PharmaEngine total liabilities. Based on the latest financial reports, PharmaEngine (4162) has total liabilities worth NT$112.86 Million TWD (≈ $3.56 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check PharmaEngine asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of PharmaEngine (2009–2024)
Total liabilities of PharmaEngine from 2009 to 2024. This chart illustrates how PharmaEngine's total liabilities have evolved over time, based on quarterly financial data.
PharmaEngine Competitors by Total Liabilities
The table below lists competitors of PharmaEngine ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Eveready Industries India Limited
NSE:EVEREADY
|
India | Rs5.91 Billion |
|
Cohen & Steers Real Estate Opportunities and Income Fund
NYSE:RLTY
|
USA | $143.70 Million |
|
Cahya Mata Sarawak Bhd
KLSE:2852
|
Malaysia | RM801.52 Million |
|
SIM Acquisition Corp. I Unit
NASDAQ:SIMAU
|
USA | $10.95 Million |
|
Ive Group Ltd
AU:IGL
|
Australia | AU$557.53 Million |
|
Caisse régionale de Crédit Agricole Mutuel d-Ille-et-Vilaine SC
PA:CIV
|
France | €18.62 Billion |
|
NIIT LEARNING SYSTEMS LTD
NSE:NIITMTS
|
India | Rs-15.43 Billion |
Liability Composition Analysis (2009–2024)
This chart breaks down PharmaEngine's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 4162 total asset value.
Liquidity & Leverage Metrics
PharmaEngine Total Liabilities Ratios Explained
PharmaEngine total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 43.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.02 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.02 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PharmaEngine's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PharmaEngine (2009–2024)
The table below shows the annual total liabilities of PharmaEngine from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$448.01 Million ≈ $14.11 Million |
+392.29% |
| 2023-12-31 | NT$91.01 Million ≈ $2.87 Million |
-3.66% |
| 2022-12-31 | NT$94.47 Million ≈ $2.98 Million |
+7.71% |
| 2021-12-31 | NT$87.70 Million ≈ $2.76 Million |
-55.20% |
| 2020-12-31 | NT$195.78 Million ≈ $6.17 Million |
+22.06% |
| 2019-12-31 | NT$160.40 Million ≈ $5.05 Million |
+5.06% |
| 2018-12-31 | NT$152.67 Million ≈ $4.81 Million |
-23.63% |
| 2017-12-31 | NT$199.90 Million ≈ $6.30 Million |
+24.56% |
| 2016-12-31 | NT$160.48 Million ≈ $5.06 Million |
+102.09% |
| 2015-12-31 | NT$79.41 Million ≈ $2.50 Million |
+340.73% |
| 2014-12-31 | NT$18.02 Million ≈ $567.67K |
-30.44% |
| 2013-12-31 | NT$25.90 Million ≈ $816.09K |
+82.39% |
| 2012-12-31 | NT$14.20 Million ≈ $447.44K |
-8.90% |
| 2011-12-31 | NT$15.59 Million ≈ $491.17K |
+12.60% |
| 2010-12-31 | NT$13.85 Million ≈ $436.19K |
-54.60% |
| 2009-12-31 | NT$30.50 Million ≈ $960.76K |
-- |
About PharmaEngine
PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. The company is developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hematol… Read more